5 More Countries Approve Pfizer Arthritis Drug Xeljanz

Law360, New York (July 15, 2013, 6:03 PM ET) -- Pfizer Inc.'s rheumatoid arthritis drug Xeljanz has received approval for use in five more countries, including Switzerland, the company said Monday, adding that it hoped a European Union health board would soon reverse a negative review of the drug.

Pfizer said the 5-milligram version of its twice-a-day pill for adults with moderate-to-severe rheumatoid arthritis has been approved in Argentina, Kuwait and the United Arab Emirates, while the 5- and 10-milligram versions have been approved in Russia and Switzerland. Switzerland is the first European country to approve the...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers